| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Bifeprunox targets dopamine D2 receptors and serotonin 5-HT1A receptors, acting as a partial agonist at both. As a partial agonist at D2 receptors, it provides sufficient dopaminergic activity to reduce psychotic symptoms while minimizing the risk of extrapyramidal side effects associated with full D2 antagonists. As a partial agonist at 5-HT1A receptors, it may provide additional antidepressant and anxiolytic effects. This dual mechanism is characteristic of atypical antipsychotics.
|
|---|---|
| ln Vitro |
For the h5-HT1A receptor, bifeprunox has an Emax of 70% and a pKi of 8 [1].
In vitro, Bifeprunox demonstrates partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors. Its activity can be assessed by measuring its ability to activate receptor-mediated signaling pathways, such as inhibition of forskolin-stimulated cAMP accumulation (for D2) or stimulation of [³⁵S]GTPγS binding. The compound's partial agonist activity is characterized by lower efficacy than full agonists but higher efficacy than antagonists. Its selectivity for D2 and 5-HT1A over other receptors is assessed. |
| ln Vivo |
In mice, marble burying is decreased by bifeprunox (0.001-2.5 mg/kg) [2]. Rats' responses to drug-related cues alter their behavior when they seek nicotine when exposed to bifeprunox (4–250 μg/kg) [3].
In vivo, Bifeprunox has been investigated as an atypical antipsychotic for the treatment of schizophrenia. As a partial agonist at D2 and 5-HT1A receptors, it modulates dopaminergic and serotonergic neurotransmission, reducing psychotic symptoms. Its partial agonist activity at D2 receptors may provide a more favorable side effect profile compared to typical antipsychotics, with reduced risk of extrapyramidal symptoms. The compound has been evaluated in preclinical and clinical studies for its antipsychotic efficacy. |
| Enzyme Assay |
The in vitro receptor binding assay for Bifeprunox involves competition binding experiments using membrane preparations from cells expressing human dopamine D2 or serotonin 5-HT1A receptors. Radioligands specific for each receptor type, such as [³H]spiperone for D2 or [³H]8-OH-DPAT for 5-HT1A, are used. Membranes are incubated with varying concentrations of the test compound and the radioligand at room temperature for 60-120 minutes. Nonspecific binding is determined in the presence of excess unlabeled appropriate ligand. Bound radioactivity is separated by filtration and quantified by scintillation counting. Ki values are calculated using the Cheng-Prusoff equation.
|
| Cell Assay |
For in vitro functional assays, Bifeprunox is evaluated using cells expressing dopamine D2 or serotonin 5-HT1A receptors. Receptor activation is assessed by measuring agonist-induced inhibition of forskolin-stimulated cAMP accumulation (for D2) or stimulation of [³⁵S]GTPγS binding. Cells are treated with varying concentrations of the compound, and EC50 values are calculated from dose-response curves. The partial agonist activity is confirmed by comparing the compound's maximal response to that of full agonists.
|
| Animal Protocol |
In vivo animal experiments for Bifeprunox typically use rodent models of schizophrenia, such as the conditioned avoidance response test, amphetamine-induced locomotor activity, or prepulse inhibition of startle. Animals are administered the compound orally or intraperitoneally at various doses. Behavioral responses are assessed at various time points post-administration. Catalepsy tests are performed to assess extrapyramidal side effect liability. The compound's effects are compared to other atypical antipsychotics. Pharmacokinetic studies are conducted to determine bioavailability and brain penetration.
|
| References |
[1]. Newman-Tancredi A, et al. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005 Sep;8(3):341-56.
[2]. Bruins Slot LA, et al. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol. 2008 Mar;19(2):145-52. [3]. Di Clemente A, et al. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. Addict Biol. 2012 Mar;17(2):274-86. |
| Molecular Formula |
C25H27N3O5S
|
|---|---|
| Molecular Weight |
481.56398
|
| Exact Mass |
481.167
|
| CAS # |
350992-13-1
|
| Related CAS # |
Bifeprunox;350992-10-8
|
| PubChem CID |
6918587
|
| Appearance |
Light yellow to light brown solid powder
|
| LogP |
4.698
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(O)=O.O=C1NC2=C(C(N3CCN(CC4C=CC=C(C5=CC=CC=C5)C=4)CC3)=CC=C2)O1
|
| InChi Key |
ONWKHSGOYGLGPO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23N3O2.CH4O3S/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19;1-5(2,3)4/h1-11,16H,12-15,17H2,(H,25,28);1H3,(H,2,3,4)
|
| Chemical Name |
methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
|
| Synonyms |
DU127090 Bifeprunox DU-127090Bifeprunox Mesylate DU 127090
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~51.9 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0766 mL | 10.3829 mL | 20.7658 mL | |
| 5 mM | 0.4153 mL | 2.0766 mL | 4.1532 mL | |
| 10 mM | 0.2077 mL | 1.0383 mL | 2.0766 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
